<DOC>
	<DOCNO>NCT00804050</DOCNO>
	<brief_summary>This prospective , randomized multicenter phase III clinical trial design evaluate safety activity comparison Erythropoietin Erythropoietin Associated Differentiating Therapy With Acid 13-Cis-Retinoic Dihydroxyvitamin D3 Myelodysplastic Syndromes Without Excess Blasts</brief_summary>
	<brief_title>Multicentric Study Comparison Between Erythropoietin Erythropoietin Associated Differentiating Therapy With Acid 13-cis-retinoic Dihydroxyvitamin D3 Myelodysplastic Syndromes Without Excess Blasts</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Dihydroxycholecalciferols</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>1 . Age high 18 ; 2 . Confirmed diagnosis osseous biopsy bone marrow cytomorphologic count blast cell , Myelodysplastic syndrome without excess blast : `` refractary anemia '' , `` refractary anemia ring sideroblast '' , `` refractary citopenya multilineage dysplasia '' , `` refractary citopenya multilineage dysplasia ring sideroblast '' `` 5qsyndrome '' without excess blast base WHO classification ( appendix ) . 3 . Low intermediate1 IPSS ( appendix ) . 4 . Hb &lt; 11g/dl . 5. rEPO serum level &lt; 500mU/L . 6 . Women menopause least one year . 7 . Informed consent 1 . Myelodisplastic syndrome excess blast ( RAEB ) . 2 . IPSS score intermediate2 high ( appendix ) . 3 . Forecasted allogeneic bone marrow transplant within 1 year diagnosis ( patient younger 60 year , transfusion dependent serious leuko/thrombocytopenia HLA compatible family donor ) .Considering time need perform procedure , indication transplant nonconsanguineous donor contraindication inclusion protocol response rEPO therapy Â± differentiate therapy . 4 . Renal failure creatininemia value great 3 time normal limit . 5 . Chronic hepatophaty bilirubinemia value great 3 time normal limit and/or AST ALT ALP value great 5 time normal limit . 6 . Presence second tumor serious pathology life expectancy lower one year . 7 . Presence neurologic psychiatric pathology make patient unreliable acquisition drug . 8 . Allergy/intolerance know use drug . 9 . Pregnant woman . 10 . Women childbearing age menopause less one year . 11 . Age &lt; 18 year old . 12 . HIV positive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Acid 13-Cis-Retinoic</keyword>
	<keyword>Dihydroxyvitamin D3</keyword>
	<keyword>low intermediate-1 IPSS</keyword>
	<keyword>MDS low risk</keyword>
</DOC>